EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 3.0

Results of high-risk neutropenia therapy of hematology–oncology patients in a university hospital in Uruguay

Matilde Boada Burutaran, Regina Guadagna, Sofia Grille, Mariana Stevenazzi, Cecilia Guillermo, Lilian Diaz

Revista Brasileira de Hematologia e Hemoterapia · 2015-01 · 37 (1) · 28-33

DOI: 10.1016/j.bjhh.2014.11.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Brasileira de Hematologia e Hemoterapia, 2015-01. Verfasst von Matilde Boada Burutaran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universidad de la República, Montevideo, Uruguay. Electronic address: matilde_boada@hotmail.com. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia.

Methods

A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service.

Results

Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5% of all microbiologically documented infections. Treatment of 63% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5%.

Conclusion

The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.

Schlagwörter

Stichwörter der Autor:innen

Clinical protocolsDrug resistance, bacterialGram-negative bacterial infectionsHematologic diseasesNeutropenia

Autor:innen und Institutionen

  • Universidad de la República, Montevideo, Uruguay. Electronic address: matilde_boada@hotmail.com.
  • Universidad de la República, Montevideo, Uruguay.

Zitieren

APA

Boada Burutaran, M., Guadagna, R., Grille, S., Stevenazzi, M., Guillermo, C., & Diaz, L. (2015). Results of high-risk neutropenia therapy of hematology–oncology patients in a university hospital in Uruguay. Revista Brasileira de Hematologia e Hemoterapia, 37(1), 28-33. https://doi.org/10.1016/j.bjhh.2014.11.012

Vancouver

Boada Burutaran M, Guadagna R, Grille S, Stevenazzi M, Guillermo C, Diaz L. Results of high-risk neutropenia therapy of hematology–oncology patients in a university hospital in Uruguay. Revista Brasileira de Hematologia e Hemoterapia. 2015;37(1):28-33. doi:10.1016/j.bjhh.2014.11.012

BibTeX
@article{BoadaBurutaran2015,
  author = {Boada Burutaran, Matilde and Guadagna, Regina and Grille, Sofia and Stevenazzi, Mariana and Guillermo, Cecilia and Diaz, Lilian},
  title = {Results of high-risk neutropenia therapy of hematology–oncology patients in a university hospital in Uruguay},
  journal = {Revista Brasileira de Hematologia e Hemoterapia},
  year = {2015},
  volume = {37},
  number = {1},
  pages = {28--33},
  doi = {10.1016/j.bjhh.2014.11.012}
}
Kostenlos starten →